Tevogen Bio Holdings Inc. Material Event: Understanding the Reverse Stock Split

Tevogen Bio Holdings Inc. recently announced a significant corporate action: a reverse stock split. This summary breaks down the details of this event, its implications for investors, and what it means for the company's future, all in clear, straightforward language.

1. What happened?

Tevogen Bio announced a 1-for-50 reverse stock split.

To understand this, imagine you have 50 small pieces of a pie. After the split, those 50 pieces combine into just 1 much larger piece. You still have the same total amount of pie, but it is now in fewer, bigger portions.

In stock terms, if you owned 50 shares of Tevogen Bio stock, you will now own 1 share. However, that single share will theoretically be worth 50 times more than each of your old shares. Therefore, the total value of your investment immediately after the split should remain the same as before the split.

2. When did it happen?

The company officially filed the paperwork for this action on March 3, 2026. The reverse stock split will become effective at the open of business on March 6, 2026, which is when the stock will begin trading at its new, higher price per share.

3. Why did it happen?

Companies typically execute a reverse stock split for a few key reasons. For Tevogen Bio, the primary driver is to boost its share price to meet Nasdaq's listing requirements.

The Nasdaq exchange mandates that a company's stock must trade above $1.00 per share to maintain its listing. If a stock trades below this threshold for too long, the company faces delisting. Delisting can severely impact its ability to attract investors and raise capital. Given Tevogen Bio's recent trading history, where its stock has been significantly below the $1.00 mark (for example, if it was trading around $0.05 per share), a reverse split becomes a necessary step to regain compliance.

While the filing itself focuses on the mechanics, a low share price often points to challenges in a company's business performance, financial health, or market sentiment. As a clinical-stage biotechnology company, Tevogen Bio faces inherent risks associated with drug development. These include the high costs of research and development, the uncertainty of clinical trial success, and the lengthy path to commercialization. Such factors can lead to significant cash burn and investor skepticism, ultimately driving down share price.

Tevogen Bio's stockholders approved this move at a special meeting on February 19, 2026. They granted the company's Board of Directors the authority to determine the exact ratio (between 1-for-25 and 1-for-85) and the timing. The Board chose a 1-for-50 ratio, indicating the extent of the share price adjustment required.

4. Why does this matter?

This significant corporate action impacts how the stock appears and trades, with broader implications for the company's future:

• Higher Share Price: The stock price per share will immediately jump. For instance, if the stock traded at $0.05 before the split, it would theoretically trade at $2.50 ($0.05 x 50) after the split, moving it above the critical $1.00 Nasdaq threshold.
• Meeting Exchange Requirements: Maintaining its listing on Nasdaq is crucial for Tevogen Bio. This helps the company attract institutional investors, ensure liquidity for its shares, and access capital markets for future funding – all vital for a biotech company.
• Perception: A higher share price can make a stock appear more "legitimate" or attractive to institutional investors (e.g., large funds). Many institutional policies prevent investment in very low-priced stocks (often called "penny stocks") due to perceived higher risk and volatility.
• Fractional Shares: If your share count is not perfectly divisible by 50 (e.g., 75 shares), you will not receive a fractional share. Instead, Tevogen Bio will pay you cash for that fractional portion, calculated based on the stock's closing price the day before the split. This means your total share count will be rounded down.
• Warrants and Convertible Securities: If you own warrants or other convertible securities, these will also be adjusted. The number of shares they convert into will be divided by 50, and their exercise price will be multiplied by 50, reflecting the new share structure.
• Impact on Market Capitalization and Shares Outstanding: While the price per share increases, the total number of outstanding shares will decrease proportionally. For instance, 5 billion shares outstanding before the split would become 100 million shares after. The company's market capitalization (total value of all shares) should remain unchanged immediately after the split, assuming no shift in investor sentiment.

5. Tevogen Bio's Business and Strategy (Beyond the Split)

It is important to remember that a reverse stock split is a financial maneuver, not a change in the company's core business or a solution to underlying operational challenges. Tevogen Bio is a clinical-stage biotechnology company focused on developing off-the-shelf, allogeneic T-cell immunotherapies for cancer and viral infections. Its lead product candidate, TVGN-489, is currently in clinical trials.

For investors, Tevogen Bio's long-term value will depend on:

• Clinical Trial Success: Positive outcomes from its ongoing and future clinical trials are paramount.
• Regulatory Approvals: The ability to secure regulatory approvals for its therapies.
• Commercialization Strategy: Its plan to bring approved products to market and generate revenue.
• Financial Management: Its ability to manage cash burn, secure additional funding, and move towards profitability.

6. Who is affected?

• Current Investors/Traders: This directly affects your holdings. You will see fewer shares in your account, but each share will carry a higher price. Your total investment value should remain the same initially.
• Tevogen Bio Itself: The company benefits by potentially meeting Nasdaq listing requirements, which helps maintain its public profile and access to capital markets.
• Potential Future Investors: A higher share price might make the stock more appealing to a broader range of investors, particularly institutional funds.

7. What happens next?

Starting March 6, 2026, Tevogen Bio's common stock will begin trading on Nasdaq on a "post-split" basis. You will see the new, higher price per share and the reduced number of shares in your brokerage account. The company's ticker symbol will remain TVGN, but its CUSIP number (a unique identification number for securities) will change to 88165K200 to reflect the new security structure.

The company will continue its operations, now with a stock that meets the exchange's price requirements. However, the market will closely watch for signs of fundamental business improvement to sustain the higher share price.

8. What should investors/traders know?

• A Cosmetic Change (Initially), but Underlying Business Matters: A reverse stock split does not change the company's fundamental value or your total investment at the moment of the split. However, it often signals underlying business challenges that led to a low share price. The split itself addresses a compliance issue but does not resolve these deeper challenges.
• Volatility and Potential Price Erosion: While the initial value remains the same, the market often reacts to reverse splits with increased volatility. Some investors view it as a sign of a struggling company. Without significant positive business developments, the stock price can sometimes drift back down over time, potentially leading to future compliance issues.
• Fractional Shares: If you hold a number of shares not evenly divisible by 50, you will receive cash for the fractional part. This means your total share count will be rounded down, resulting in a slightly smaller equity position in the company.
• Due Diligence is Key: Do not let the higher share price mislead you. Focus on the company's long-term prospects, clinical trial progress, financial health (cash position, burn rate, path to profitability), and strategic execution, rather than solely the share price change from the split.
• No Need to Panic (or Get Overly Excited): Understand that this is a corporate restructuring of shares. Your broker will automatically handle the conversion, but it is always prudent to check your account on or after March 6, 2026, to confirm your new share count and price.
• Risk of Further Dilution: If the company continues to burn cash and needs to raise capital, it may issue new shares, which could dilute the value of existing shareholders' investments.